NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00700544,Treatment Outcome in Elderly Patients,https://clinicaltrials.gov/study/NCT00700544,,COMPLETED,"A multicenter randomized trial evaluating the possible benefit of androgens during post remission therapy in an attempt to improve the outcome of AML in older patients.All patients received the ICL regimen as induction and were randomized to receive, after achieving CR or PR, a maintenance therapy including or not androgens. Patients randomized with androgens additionally received 10 to 20 mg according to body weigh of norethandrolone daily for up to 2 years",NO,AML|Elderly Patients,DRUG: chemotherapy treatment (see arm) + norethandrolone|DRUG: chemotherapy treatment (see arms),"The primary objective of this study was to assess the ability of androgens to increase DFS., 3 years","The secondary objective was to improved EFS and OS and to assess side effects and toxicity of androgenotherapy, 3 years",,"University Hospital, Grenoble",French Innovative Leukemia Organisation|BGMT,ALL,"ADULT, OLDER_ADULT",PHASE3,330,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,LAM SA 2002,2002-06,2005-04,2008-05,2008-06-18,,2008-06-18,"Arnaud PIGNEUX, Pessac, 33604, France",
